Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1

John R. Mascola, Stuart W. Snyder, Owen S. Weislow, Seifu M. Belay, Robert B. Belshe, David H. Schwartz, Mary Lou Clements, Raphael Dolin, Barney S. Graham, Geoffrey J. Gorse, Michael C. Keefer, M. Juliana McElrath, Mary Clare Walker, Kenneth F. Wagner, John G. McNeil, Francine E. McCutchan, Donald S. Burke

Research output: Contribution to journalArticle

Abstract

Phase I studies of volunteers not infected with human immunodeficiency virus type 1 (HIV-1) have shown that immunization with envelope subunit vaccine products elicits antibodies that neutralize laboratory-adapted (prototype) HIV-1 strains in vitro. Prototype strains are adapted to grow in continuous (neoplastic) cell lines and are more susceptible to neutralization than are primary isolates cultured in human peripheral blood mononuclear cells. In this study, 50 sera from nine phase I vaccine trials and 16 from HIV-1-infected persons were evaluated for neutralizing antibody activity against 3 laboratory-adapted and 5 primary HIV-1 isolates. Of 50 sera, 49 neutralized at least 1 of the prototype strains: however, none displayed neutralizing activity against primary isolates of HIV-1. Serum from most HIV- 1-infected persons neutralized both laboratory-adapted and primary HIV-1 isolates. These data demonstrate a qualitative, or large quantitative, difference in the neutralizing antibody response induced by envelope subunit vaccination and natural HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)340-348
Number of pages9
JournalJournal of Infectious Diseases
Volume173
Issue number2
StatePublished - 1996
Externally publishedYes

Fingerprint

Subunit Vaccines
Neutralizing Antibodies
HIV-1
Immunization
Serum
Virus Diseases
Antibody Formation
Volunteers
Blood Cells
Vaccination
Vaccines
Cell Line
Antibodies

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Mascola, J. R., Snyder, S. W., Weislow, O. S., Belay, S. M., Belshe, R. B., Schwartz, D. H., ... Burke, D. S. (1996). Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. Journal of Infectious Diseases, 173(2), 340-348.

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. / Mascola, John R.; Snyder, Stuart W.; Weislow, Owen S.; Belay, Seifu M.; Belshe, Robert B.; Schwartz, David H.; Clements, Mary Lou; Dolin, Raphael; Graham, Barney S.; Gorse, Geoffrey J.; Keefer, Michael C.; McElrath, M. Juliana; Walker, Mary Clare; Wagner, Kenneth F.; McNeil, John G.; McCutchan, Francine E.; Burke, Donald S.

In: Journal of Infectious Diseases, Vol. 173, No. 2, 1996, p. 340-348.

Research output: Contribution to journalArticle

Mascola, JR, Snyder, SW, Weislow, OS, Belay, SM, Belshe, RB, Schwartz, DH, Clements, ML, Dolin, R, Graham, BS, Gorse, GJ, Keefer, MC, McElrath, MJ, Walker, MC, Wagner, KF, McNeil, JG, McCutchan, FE & Burke, DS 1996, 'Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1', Journal of Infectious Diseases, vol. 173, no. 2, pp. 340-348.
Mascola, John R. ; Snyder, Stuart W. ; Weislow, Owen S. ; Belay, Seifu M. ; Belshe, Robert B. ; Schwartz, David H. ; Clements, Mary Lou ; Dolin, Raphael ; Graham, Barney S. ; Gorse, Geoffrey J. ; Keefer, Michael C. ; McElrath, M. Juliana ; Walker, Mary Clare ; Wagner, Kenneth F. ; McNeil, John G. ; McCutchan, Francine E. ; Burke, Donald S. / Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. In: Journal of Infectious Diseases. 1996 ; Vol. 173, No. 2. pp. 340-348.
@article{2599d0901fa44a56ae785c6e76b4c198,
title = "Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1",
abstract = "Phase I studies of volunteers not infected with human immunodeficiency virus type 1 (HIV-1) have shown that immunization with envelope subunit vaccine products elicits antibodies that neutralize laboratory-adapted (prototype) HIV-1 strains in vitro. Prototype strains are adapted to grow in continuous (neoplastic) cell lines and are more susceptible to neutralization than are primary isolates cultured in human peripheral blood mononuclear cells. In this study, 50 sera from nine phase I vaccine trials and 16 from HIV-1-infected persons were evaluated for neutralizing antibody activity against 3 laboratory-adapted and 5 primary HIV-1 isolates. Of 50 sera, 49 neutralized at least 1 of the prototype strains: however, none displayed neutralizing activity against primary isolates of HIV-1. Serum from most HIV- 1-infected persons neutralized both laboratory-adapted and primary HIV-1 isolates. These data demonstrate a qualitative, or large quantitative, difference in the neutralizing antibody response induced by envelope subunit vaccination and natural HIV-1 infection.",
author = "Mascola, {John R.} and Snyder, {Stuart W.} and Weislow, {Owen S.} and Belay, {Seifu M.} and Belshe, {Robert B.} and Schwartz, {David H.} and Clements, {Mary Lou} and Raphael Dolin and Graham, {Barney S.} and Gorse, {Geoffrey J.} and Keefer, {Michael C.} and McElrath, {M. Juliana} and Walker, {Mary Clare} and Wagner, {Kenneth F.} and McNeil, {John G.} and McCutchan, {Francine E.} and Burke, {Donald S.}",
year = "1996",
language = "English (US)",
volume = "173",
pages = "340--348",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1

AU - Mascola, John R.

AU - Snyder, Stuart W.

AU - Weislow, Owen S.

AU - Belay, Seifu M.

AU - Belshe, Robert B.

AU - Schwartz, David H.

AU - Clements, Mary Lou

AU - Dolin, Raphael

AU - Graham, Barney S.

AU - Gorse, Geoffrey J.

AU - Keefer, Michael C.

AU - McElrath, M. Juliana

AU - Walker, Mary Clare

AU - Wagner, Kenneth F.

AU - McNeil, John G.

AU - McCutchan, Francine E.

AU - Burke, Donald S.

PY - 1996

Y1 - 1996

N2 - Phase I studies of volunteers not infected with human immunodeficiency virus type 1 (HIV-1) have shown that immunization with envelope subunit vaccine products elicits antibodies that neutralize laboratory-adapted (prototype) HIV-1 strains in vitro. Prototype strains are adapted to grow in continuous (neoplastic) cell lines and are more susceptible to neutralization than are primary isolates cultured in human peripheral blood mononuclear cells. In this study, 50 sera from nine phase I vaccine trials and 16 from HIV-1-infected persons were evaluated for neutralizing antibody activity against 3 laboratory-adapted and 5 primary HIV-1 isolates. Of 50 sera, 49 neutralized at least 1 of the prototype strains: however, none displayed neutralizing activity against primary isolates of HIV-1. Serum from most HIV- 1-infected persons neutralized both laboratory-adapted and primary HIV-1 isolates. These data demonstrate a qualitative, or large quantitative, difference in the neutralizing antibody response induced by envelope subunit vaccination and natural HIV-1 infection.

AB - Phase I studies of volunteers not infected with human immunodeficiency virus type 1 (HIV-1) have shown that immunization with envelope subunit vaccine products elicits antibodies that neutralize laboratory-adapted (prototype) HIV-1 strains in vitro. Prototype strains are adapted to grow in continuous (neoplastic) cell lines and are more susceptible to neutralization than are primary isolates cultured in human peripheral blood mononuclear cells. In this study, 50 sera from nine phase I vaccine trials and 16 from HIV-1-infected persons were evaluated for neutralizing antibody activity against 3 laboratory-adapted and 5 primary HIV-1 isolates. Of 50 sera, 49 neutralized at least 1 of the prototype strains: however, none displayed neutralizing activity against primary isolates of HIV-1. Serum from most HIV- 1-infected persons neutralized both laboratory-adapted and primary HIV-1 isolates. These data demonstrate a qualitative, or large quantitative, difference in the neutralizing antibody response induced by envelope subunit vaccination and natural HIV-1 infection.

UR - http://www.scopus.com/inward/record.url?scp=19144365910&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19144365910&partnerID=8YFLogxK

M3 - Article

VL - 173

SP - 340

EP - 348

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -